MRPL22

Across TCGA pan-cancer cohorts, MRPL22 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of MRPL22’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where MRPL22 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MRPL22 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

KIRC, COAD, and LIHC are the cancer types where MRPL22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MRPL22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	+0.668	<.001	12	view →
COAD	Female	II,III,IV	+0.768	<.001	10	view →
LIHC	Female	II,III,IV	+0.855	<.001	9	view →
LUAD	Male	II,III,IV	+0.551	<.001	8	view →
HNSC	Male	IV	+0.525	.001	8	view →
UCEC	All	II,III,IV	+0.790	<.001	6	view →
BRCA	All	III,IV	+0.509	<.001	6	view →
BLCA	All	All	+0.345	.002	5	view →
STAD	Female	All	+0.705	.007	4	view →
KICH	All	All	−0.567	<.001	4	view →
KIRP	Male	II,III,IV	+0.426	.009	4	view →
CHOL	All	All	+1.196	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

MRPL22–KIRC

Open the KIRC breakdown →